There is epidemiological, animal and in vitro evidence that estrogen receptor β (ERβ) can mediate protective effects against colon cancer, but the mechanism is not completely understood. Previous research has indicated critical pathways whereby ERβ acts in an antitumorigenic fashion. In this study, we investigate ERβ's impact on the microRNA (miRNA) pool in colon cancer cells using large-scale genomic approaches, bioinformatics and focused functional studies. We detect and confirm 27 miRNAs to be significantly changed following ERβ expression in SW480 colon cancer cells. Among these, the oncogenic miR-17-92 cluster and miR-200a/b are strongly downregulated. Using target prediction and anticorrelation to gene expression data followed by focused mechanistic studies, we demonstrate that repression of miR-17 is a secondary event following ERβ's downregulatory effect on MYC. We show that re-introduction of miR-17 can reverse the antiproliferative effects of ERβ. The repression of miR-17 also influences cell death upon DNA damage and mediates regulation of NCOA3 (SRC-3) and CLU in colon cancer cells. We further determine that the downregulation of miR200a/b mediates increased ZEB1 while decreasing E-cadherin levels in ERβ-expressing colon cancer cells. Changes in these genes correspond to significant alterations in morphology and migration. Our work contributes novel data of ERβ and miRNA in the colon. Elucidating the mechanism of ERβ and biomarkers of its activity has significant potential to impact colon cancer prevention and treatment.
Introduction
Colorectal cancer is the third most common form of cancer among both men and women and corresponds to almost 10% of all reported cancer cases in the world (1, 2) . Women have a later onset than men (2, 3) and younger women (18-44 years old) have a better overall survival compared with men of the same age. In older women (>50 years old) this, however, is reversed (4, 5) . Hormone replacement therapy and oral contraceptives have been shown to reduce the incidence of colon cancer in women (6) (7) (8) (9) (10) (11) . Taken together, a role for the hormone estrogen is indicated in the disease development. Estrogen treatment also reduces the growth of colonocytes in non-malignant mouse cell line and reduces aberrant crypt foci in mice (12) .
Estrogen mediates its effects through two nuclear receptors: estrogen receptor α (ERα) and β (ERβ). These receptors bind estrogen with equal affinity and act as transcription factors by inducing changes in target gene expression. ERα is highly important in breast cancer where it is upregulated and increases cell proliferation. ERα is widely utilized as a therapeutic target and its activity blocked by the drug (e.g. tamoxifen). The transcriptional effect of ERα is well studied in breast cancer cells (13, 14) . In colon cancer, however, ERα is not widely expressed. The predominant ER in normal colonic epithelium is ERβ, as determined both at the protein (15) and messenger RNA (mRNA) levels (16) . Immunohistochemistry has further shown decreased expression of ERβ during colon cancer progression (17) . Polymorphism in the ERβ gene affects colon cancer risk and survival (18) (19) (20) . In vivo animal studies have demonstrated that ERβ mediates the colon cancer protective effect of estrogen (12, (21) (22) (23) (24) . Thus, there is a significant interest to determine the molecular mechanism of this receptor activity in colon cancer. ERβ has been shown to be antiproliferative in both colon cancer cells (25) (26) (27) (28) and in xenografts (26) . Recently, genome-wide analysis of protein-coding genes allowed us to identify multiple ERβ-mediated antitumorigenic effects in human colon cancer cell lines and initiate work to dissect its mechanism (29) . Exposing the wide and cell-specific impact ERβ has on gene expression (29) , we hypothesize that ERβ in part mediates these multiple effects through regulations of microRNA (miRNA).
miRNAs are short (~22 nt), single-stranded non-coding RNA regulators. They regulate gene expression through imperfect complementary binding between the miRNA 5ʹ-sequence and the 3ʹ-untranslated region of the target mRNA. Such binding mediates degradation of the mRNA transcript and/or suppression of its translation. miRNA genes are transcribed by RNA polymerase II into primary miRNAs. The nuclear protein DGCR8 and the enzyme Drosha introduce a cleavage to liberate a hairpin loop from the primary miRNAs. The resulting hairpin, precursor miRNA (premiRNA), is exported from the nucleus to the cytoplasm. The protein Dicer then cleaves the loop, leaving a short, double-stranded duplex. One strand of the duplex is released and often degraded, whereas the other strand, the mature miRNA, is incorporated into the Argonaute containing miRNA-induced silencing complex, which facilitates the interaction between the mature miRNA and its mRNA target. A miRNA can target several different genes and many of these targets are often in the same pathway (30) . As one mRNA can also be targeted by several miRNAs, the total impact of miRNAs on the transcriptome and proteome can be significant. There are about 1500 miRNA genes in the human genome (mirbase.org, January 2012) and together they may target and affect the expression of up to 60% of all protein-coding genes (31) . miRNAs have been linked to tumorigenesis due to their frequent localization at fragile sites and common breakpoint regions (32) and both oncomiRs and tumor suppressor miRNAs have been identified (33) . Altered levels of miRNAs are common in tumors, including those of the colon (34) (35) (36) .
An emerging topic in cell control and other biological processes is the regulatory connection between miRNAs and nuclear receptors (37) (38) (39) (40) (41) (42) . Estrogen has been implicated to have an effect on miRNAs in breast cancer cells (43, 44) where ERα is the predominant ER. Studies have identified ERα-regulated miRNAs (45) (46) (47) (48) (49) (50) , although it is not clear whether the regulation is directly transcriptional or indirect (51, 52) . Although recently, ERβ was indicated to affect miRNAs in breast cancer (53) , no studies so far have described miRNAs regulated by ERβ in the colon. In this study, we examined changes in the miRNA pool in cells where we previously have characterized the function of ERβ (26, 29) . In order to estimate the impact of the changed miRNA expression, we correlated changes in the miRNome with the generated transcriptome data and with the ER chromatinbinding data. Finally, we have performed focused functional studies of selected miRNAs repressed by ERβ.
Materials and methods

ERβ immunohistochemistry
Paraffin-embedded tissue arrays were first de-paraffinated in xylene and rehydrated. Antigen retrieval was achieved by immersing the slides in 10 mM citrate buffer (pH 6.0) for 15 min at 97°C. The tissues were then immersed in cold phosphate-buffered saline (PBS) and treated with 0.5% Triton-X in PBS for 15 min. Endogenous peroxidase was blocked with 0.3% H 2 O 2 in methanol for 30 min. The tissues were incubated for 10 min in 3% bovine serum albumin to block unspecific binding and treated over night with a 1:50 dilution of in-house anti-ERβ antibody ERβ 503 (54) in a humid chamber. Secondary biotinylated rabbit antichicken/turkey antibody (Invitrogen, New York, NY) was applied to the slide with the tissues and incubated for 1 h at room temperature. The slide was then treated with the Vectastain ABC solution (Vector Laboratories, Burlingame, CA), and the color was developed with 3,3ʹ-diaminobenzidine (Dako, Carpinteria, CA). Antibody washes were done with a 0.1% Nonidet P 40 substituent solution (Sigma, St Louis, MO) in PBS. The stained tissues were counterstained with hematoxylin, dehydrated, treated with xylene and mounted with Pertex mounting medium. The Olympus BX41 microscope and the Microsuite Basic Edition software from Olympus were used for visualization and imaging of the tissues.
Cell culture
Cell lines (SW480, HT29 and SW620) were obtained from American Type Culture Collection (Manassas, VA). Full-length ERβ was stably expressed via lentivirus transduction in three mixed cell populations of SW480 and HT29, with empty vectors as control, as described previously (26) . For SW620 cells, transient expression of ERβ was performed using PC3 construct with or without full-length ERβ as described previously (29) . The cells were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) with 5% fetal bovine serum and 1% penicillin-streptomycin (PEST) (Invitrogen) at 37°C with 5% CO 2 . To investigate ligand-dependent regulations, the medium was first changed to phenol-red free RPMI-1640 with 5% dextran-coated-charcoal-treated fetal bovine serum and 1% PEST 24 h before the experiments. Treatment was done for 24 h in stripped medium with 10 nM E 2 , 1 μM tamoxifen, 10 nM ICI 182780 or vehicle (EtOH).
Receptor quantification
Receptor expression was quantified using radiolabeled ligand-binding assay. Cells were plated at 500 000 cells per well in six-well plates, incubated at 37°C for 24 h and washed with PBS three times. Cells were then incubated with 0.5 nM [
3 H]estradiol in the absence or presence of 1 μM unlabeled estradiol (to measure total and unspecific binding, respectively) in 10% DCC-fetal bovine serum for 3 h at 37°C. Cells were then washed with PBS three times, lysed with lysis buffer and lysates were mixed with LSC-cocktail (Emulsifier-Safe; Packard BioScience, Waltham, MA). Radioactivity was measured using liquid scintillation counter (LS-6000-SC; Beckman-Coulter, Brea, CA). Experiments were performed in six replicates, and measurements of total protein and total cell number were performed in parallel.
RNA extraction
Total RNA was extracted with TRIzol (Invitrogen) and purified with miRNeasy spin columns (Qiagen, Chatsworth, CA), according to standard protocol. On-column DNase I digestion was used to remove remaining genomic DNA. Quantitative and qualitative RNA analyses were performed using NanoDrop 1000 spectrophotometer and the Agilent 2100 BioAnalyzer (Agilent technologies, Palo Alto, CA), respectively. Samples with RNA integrity >9.5 were used.
MiRNA expression analysis
Large-scale profiling of the miRNA pool in E 2 -treated ERβ-expressing cells and E 2 -treated control cells was made using TaqMan Low-Density Array miRNA cards, card A v2.0 (Applied Biosystems, Foster City, CA) without pre-amplification step. Total RNA, 1000 ng each, from two different mixed populations of ERβ-expressing cells and two different mixed populations of control cells was analyzed. Analysis was performed on 7900HT Fast RealTime PCR System (Applied Biosystems). MiRNAs were considered differentially expressed when the following criteria were fulfilled: Ct ≤ 32, 0.7≥FC≥1.3 and no significant difference between biological duplicates.
Complementary DNA synthesis and quantitative real-time-PCR
For miRNA analysis, poly(A) tails were added to 1 µg of total RNA with NCode miRNA First-Strand cDNA Synthesis Kit (Invitrogen) followed by complementary DNA synthesis using corresponding universal primer, according to manufacturer's protocol. For the real-time PCR reaction, a corresponding universal real-time reverse PCR primer from the kit and a forward primer based on the mature miRNA sequence (www.mirbase.org) were used. U6 was used as reference gene. For mRNA analysis, complementary DNA was synthesized from 1 µg of total RNA using Superscript III (Invitrogen) and random hexamer primers, as described previously (29) . 18S and ARHGDIA were used as reference genes. Real-time PCR was performed in 7500 Fast Real-Time PCR System (Applied Biosystems) with Fast SYBR-Green Master mix (Applied Biosystems) according to conditions specified by the manufacturer. All primer pairs were checked with melting curve analysis. Primer sequences for genes will be provided upon request. Relative expression was calculated as fold change in relation to control using the ΔΔCt-method. Unpaired two-tailed t-test was used to test significance between two parallel treatment groups of identical origin and considered significant if P < 0.05.
Bioinformatics, network and pathway analysis
Regulatory networks and biological themes affected by differentially expressed miRNAs were analyzed with Ariadne Pathway Studio v8. Predicted and confirmed target genes were correlated to previous gene expression studies (29) . Chromosomal locations of pre-miRNAs of interest were compared with ERα-, ERβ-and MYC-binding studies (55) (56) (57) .
Transfection with miRNA mimics and inhibitors
Transfection with Dharmacon miRIDIAN miRNA mimics, hairpin inhibitors and mimic or inhibitor controls were performed using DharmaFECT reagents (Thermo Scientific, Waltham, MA), essentially as described previously (58) . In brief, the cells were seeded in six-well plates in stripped serum for 24 h, then transfected in antibiotic-free medium with DharmaFECT I (0.1% of total volume) and a final concentration of 25 nM mimic, inhibitor or respective control. Medium was changed to complete medium 24 h after transfection, and the cells were cultured for an additional 24 h before harvest. All experiments were performed in triplicates.
Western blot analysis
Cells were lysed with RIPA lysis buffer. Protein concentrations were determined using Qubit® Protein Assay Kit (Invitrogen) along with the Qubit® 2.0 Fluorometer (Invitrogen). Approximately, 50 or 100 μg of total protein were loaded onto a 10% polyacrylamide gel. Proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis were transferred to a polyvinylidene difluoride membrane (Millipore, Billerican, MA). The membrane was blocked with 5% non-fat milk in Tris-buffered saline Tween-20 and then incubated with antibodies against NCOA3, E-cadherin (Santa Cruz Biotechnology, Santa Cruz, CA) or β-actin (catalog number: A2228; Sigma) in Tris-buffered saline Tween-20 overnight. The membrane was then reprobed with appropriate secondary antibodies conjugated with horseradish peroxidase for 2 h. Blots were processed using ECL Kit (Thermo Fisher Scientific, Rockford, IL) and exposed to film.
Proliferation study
Cells were plated in six-well plates for 24 h, transfected with miRNA mimic or control and cultured for additional 96 h. Following trypan blue staining, the cells were counted with the Countess automated cell counter (Invitrogen). All experiments were performed in triplicates.
Migration assay
Cell migration was measured using in vitro scratch assays. Cells were seeded in 12-well plates and were allowed to attach for 24 h after which an artificial gap was created in the confluent cell monolayer with a pipette tip. If treated with miRNA mimics, the cells were then transfected 24 h before the gap was introduced. The medium was replaced with fresh medium after the cells were washed twice with pre-warmed PBS to remove the debris and to smooth the edges of the scratch. Initial images of the scratch (0 h) were taken with Olympus 1X51 inverted microscope, after which the cells were incubated in a 5% CO 2 cell incubator at 37°C. Plates were taken out of the incubator intermittently to measure cell migration; images of the scratch were taken at 4 and 8 h following the initial scratch and image acquisition. Distance of migration and area covered by migrating cells were analyzed quantitatively from the acquired images by using Olympus cellSens® digital imaging software and ImageJ software, respectively.
Apoptosis assay SW480 control cells were transfected with miR-17 inhibitor and control for 48 h, then treated with vehicle (dimethyl sulfoxide) or the DNA-damaging agent cisplatin (cis-diammineplatinum(II) dichloride) (Sigma-Aldrich, St Louis, MO) with a final concentration of 10 μg/ml for 24 h. Cells were stained with trypan blue and counted as described previously. Statistical analysis was made with Chi-square test between amount of live and dead control cells with endogenous miR-17 expression, and cells were transfected with miR-17 inhibitor, treated with either dimethyl sulfoxide or cisplatin.
Results
Expression of ERβ in normal colonic epithelium
As previous studies investigating ERβ expression in colon have not thoroughly differentiated between ERβ wild-type and splice variants, we investigated the expression pattern using our in-house wild-type-specific ERβ503 antibody (54, 59 ). This polyclonal anti-ERβ was used on tissue microarrays containing 46 1 mm 2 cores of different types of normal tissue and 216 cores representing the 20 most common forms of human cancer. We focused on the 15 sections from normal intestinal tract and 27 sections of colon carcinoma from different individuals. A widespread expression of ERβ was observed in both males and females throughout the normal intestinal tract, exemplified in Figure 1A . Nuclear ERβ expression was present in the epithelial cells of the duodenum, small and large intestine and the rectum ( Figure 1A ), whereas other tissue samples (e.g. liver) on the same array showed no nuclear ERβ staining (Supplementary Figure 1 , available at Carcinogenesis Online). Although ERβ was still expressed in the colorectal tumors, the extent of nuclear staining was noticeably lower and weaker than in normal intestine. The cytoplasmic staining, on the other hand, did not seem to decrease in the tumors. Consistent with previous reports (17) , the lymphocytes in the normal colon were positive for ERβ, whereas negative for the colorectal cancer tissues. The Human Protein Atlas (http://www.proteinatlas.org) offers a large database with protein profiling of human normal and cancer tissues as well as cell lines (60) . Here, three different and characterized antibodies against ERα revealed no expression of ERα in tissues from the intestinal tract or in colon cancer ( Figure 1A ). These findings, together with previous reports, solidly demonstrate that ERβ is the predominant ER in colonic epithelia. This supports the notion that the protective effects of estrogen in colon carcinogenesis are mediated by ERβ in colon epithelial cells and emphasizes the need to elucidate their mechanism(s). As miRNAs affect cancer development and, also, are promising as biomarkers and as therapeutic agents, we investigated whether ERβ affects miRNAs in colorectal cancer cells.
Exogenously expressed ERβ are within physiological ranges
To investigate the mechanism of ERβ action, one needs cell lines expressing this receptor. As ERβ is not expressed at sufficient levels in colorectal cancer cell lines (29, 61) it is necessary to express it exogenously. We have previously established and characterized cell lines with stable ERβ expression (26, 29) . We and others have noted that ERβ when re-introduced in colon cancer cell lines is ligand independent (25, 26, 29) . To determine whether the level of expression in our cell lines is physiological, we performed radiolabeled ligandbinding assays. Cell lines with or without ERβ were incubated with 1 nM [3H]estradiol in the absence or presence of 1000 nM unlabeled estradiol and total and unspecific binding were recorded, as shown in Figure 1B . The resulting expression levels were calculated and correspond to 3 770 ± 940 receptors/cell (6.3 fmol/10 6 cells) for stably transfected SW480-ERβ, 2 470 ± 597 receptors/cell (4.1 fmol/10 6 cells) for stably transfected HT29-ERβ cells and 3 325 ± 307 receptors/cell (5.5 fmol/10 6 cells) for transiently transfected SW620, which falls within physiological ranges (62, 63) . None of the parental or control cell lines showed significant levels of binding, supporting the lack of endogenous ER expression. Thus, the exogenously introduced ERβ is expressed at levels that are physiologically relevant and binds ligand.
Introduction of ERβ in SW480 colon cancer cells changes the miRNA pool
To investigate whether ERβ has an effect on miRNA expression in colon cancer cells, we compared estrogen-treated SW480 control cells to estrogen-treated ERβ-expressing SW480 cells using large-scale miRNA techniques. The results indicate that ERβ expression induced a significant change in the mature miRNA pool; a total of 51 miRNAs were scored as downregulated and 43 as upregulated (Supplementary  Table 1 , available at Carcinogenesis Online). Confirmations using real-time PCR were performed for a total of 60 miRNAs, out of which 27 confirmed the large-scale analysis results. The regulations of the remaining 33 miRNAs are inconclusive due to issues with primer specificity, detection levels or inconsistent regulations between the three mixed cell populations. Table I summarizes the confirmed  miRNAs and Figures 2 and 3A show real-time PCR results. Of the confirmed miRNAs, 24 were downregulated and miR-205, miR-10a/b were the only three miRNAs confirmed as upregulated. We found the entire miR-17-92 cluster, also known as oncomir-1, to be downregulated in ERβ-expressing cells ( Figure 3A ). This study shows for the first time that introduction of ERβ induces a change of the miRNA pool in colon cancer cells.
The changed miRNA pool contributes to the ERβ-induced transcriptome
MiRNAs can induce degradation of their target mRNAs and we have observed large changes in the mRNA expression as a result of ERβ in these cells (29) . To understand the impact of the changed miRNA pool on the SW480 transcriptome, we identified the predicted and/ or confirmed target genes of the regulated miRNAs. An anticorrelation between the ERβ-regulated miRNome and the transcriptome of protein-coding genes, using bioinformatics, indicates that the impact of the changed miRNA pool could be substantial (illustrated in Supplementary Figure 2 , available at Carcinogenesis Online). We note several clusters that appear particularly implicated, such as the one of miR-9, which is predicted to target and regulate multiple genes that were regulated by ERβ expression. Other miRNA targets that are implicated in colon carcinogenesis include ANAX1 that was upregulated upon ERβ expression. ANAX1 is a predicted target of miR-196a-1, which is correspondingly downregulated upon ERβ expression. ANAX1 inhibits nuclear factor-κB and inflammatory response in the colon and mediates antitumorigenic effects (64) . We have previously reported that ERβ mediates anti-inflammatory effects, including the repression of IL-6, and hypothesized that nuclear factor-κB contributes to its tumor-protective properties (29) . This was recently confirmed in vivo where knock-out of ERβ in mice increased nuclear factor-κB and IL-6 expression and corresponding inflammatory response in the colon, and significantly enhanced intestinal tumor development (24) . The impact of miR-196a-1 in this context requires further investigation. Further, many tumor suppressors that were upregulated by ERβ, may be targeted by the miRNAs, found to be downregulated in this study. DLC1, which can inhibit proliferation in colon cancer cell lines (65) , and cyclin D1 are both predicted targets of miR-19a and tumor suppressor LATS2 (66,67) by miR-25. All these genes are not necessarily regulated only as a consequence of the ERβ-affected miRNAs; however, exploring these networks is likely to contribute to elucidating the mechanism of transcriptional regulation by ERβ. These results may thus serve as a guide for future studies to investigate ERβ transcriptional regulation.
ERβ regulates miRNAs with known ERβ DNA-binding sites nearby
A relevant question is whether the observed change in the miRNA pool is a direct or indirect result of ERβ transcriptional activity. None of the proteins and enzymes in the miRNA processing apparatus, such as DGCR8, Drosha, Dicer or Argonaut, were significantly changed at their transcriptional levels following ERβ expression (Supplementary Table 2 , available at Carcinogenesis Online). This suggested that changes in the miRNA pool were a consequence of transcriptional regulation. We investigated whether the regulated miRNAs had an ER chromatin-binding sites close to their chromosomal locations. The high homology of the DNAbinding domain between ERα and ERβ allows these receptors to frequently bind to the same estrogen responsive elements (EREs). Published studies have identified endogenous ERα binding (55, 56) and/or exogenous ERβ binding (55, 57) to the genome in the human breast cancer cell line MCF-7. No such studies have been performed in colon cancer cells. We may, however, assume that ERβ is capable of binding to the identified chromatin positions also in colon cancer cells. By correlating the chromosomal location of regulated miRNAs with published ERα-and ERβ-binding sites, we could identify miRNAs with one or several proximal and distal ERβ-or ERα-binding sites, as summarized in Table II . The 27 regulated mature miRNA sequences can be coded for by 35 different pre-miRNAs. Out of these 35 pre-miRNAs, 23 had an ERβ-binding site within 100 kb. 
←
Thus, up to 66% of pre-miRNAs are potentially transcriptionally regulated by ERβ. We note that the most upregulated miRNA, miR10a, has the closest reported ERβ-binding site 23 kb upstream of the miRNA gene (55 Figure 3A , available at Carcinogenesis Online). Future studies are needed to explore the details of ERβ transcriptional regulation, including defining its chromatin-binding sites in colon cells.
ERβ affects miRNAs through repression of MYC
Several of the regulated miRNAs do not have a known ERβ-binding site in their proximity. Although the ERs can regulate genes distant from their chromatin-binding site (68), we assumed that miRNAs were also regulated as a result of secondary events. We have previously observed that the proto-oncogene MYC is strongly downregulated following ERβ expression in these and other cells (13, 26, 29) , and ERβ binds the MYC promoter within 70 kb indicating that MYC is directly regulated by ERβ (55, 57) . MYC is a key regulator of miRNAs (69) (70) (71) , which contributes to its oncogenic effect (72) . We note that ERβ mediates a 50% decrease in MYC levels in SW480 cells ( Figure 3B , left panel). We correlated our regulated miRNAs with MYC chromatin-binding sites (56) and previously published data on MYC and miRNA regulation in other cell lines (69, 71, 73, 74) , summarized in Table III . Several MYCregulated miRNAs (miR-200a, miR-200b, miR-9-3, miR-106a and miR-135a-1) also have ERβ-binding sites in their vicinity and may be regulated by both ERβ and MYC, whereas others, including the miR-17-92 cluster, have only known MYC-binding sites. The overexpression of the latter cluster has, in colon cancer, been associated with MYC gene amplification and overexpression (75) and associated with poor survival (76) . To explore the influence of MYC on the miRNAs detected in this study in colon, we used small interfering RNA to silence MYC. The silencing of MYC was efficient and reduced its mRNA by 50% within 48 h of small interfering RNA transfection ( Figure 3B (G) Inhibition of miR-17 in SW480 cells (no E 2 ) significantly upregulated CLU and NCOA3 mRNA levels (top) and NCOA protein levels (bottom). (H) Overexpression of miR-17 (mimic, no E 2 ) decreased mRNA levels of CLU and NCOA3. Fold-change indicates the relative changes in miRNA or mRNA expression compared with controls. Unpaired two-tailed t-test was used to test the significance of differences between two parallel treatment groups of identical origin. Significance is presented as *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
MiR-17 re-expression can override the ERβ-mediated reduction of proliferation
Expression of ERβ resulted in an antiproliferative effect in the colon cancer cells. Our TaqMan Low-Density Array analysis showed that the entire miR-17-92 cluster was downregulated following ERβ expression (Table I ). This cluster consists of the following six members: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR92a-1, and all, except miR-92a, were significantly downregulated when confirmed using real-time PCR ( Figure 3A) . The members of the miR-17-92 cluster (also called Oncomir-1) are implicated in colon cancer (76) and have been related to enhanced cell proliferation (77, 78) . We selected to perform experiments using one of its key members, miR-17, to test whether the downregulation of this cluster had a significant role in the ERβ-mediated effect of proliferation. We re-introduced miR-17, using mimic, into ERβ-expressing SW480 cells and investigated whether this could oppose the ERβ-mediated repression of growth. We show that transfection with miR-17 mimic indeed can reverse the antiproliferative effects of ERβ and increase cell proliferation ( Figure 3C ).
ERβ-mediated repression of miR-17 can enhance apoptosis
The miR-17-92 cluster has also been reported to suppress apoptosis (77) . As one described function of ERβ is increased apoptosis in normal colonocytes (79) and intestines (80), we hypothesized that ERβ may mediate this apoptotic effect through this miRNA cluster. We mimicked the effect of ERβ by using a miR-17 inhibitor in SW480 cells. Although we did not observe a significant effect on apoptosis by inhibiting miR-17 in SW480 cells grown under regular conditions, we noted a clear effect on cell death when the cells were challenged with DNA-damaging cisplatin treatment. While 41% of the control cells died following cisplatin treatment, 56% of the miR-17-silenced cells died ( Figure 3D) . A Chi-square test between treated control cells (inhibitor control) and cells where miR-17 was silenced (miR-17 inhibitor) gave a P -value < 0.001. Our results show that inhibition of miR-17 caused the cells to become more sensitive to cisplatin-induced treatment. This leads us to conclude that ERβ through decreased miR-17 expression can enhance apoptosis after DNA damage in colon cells.
MiR-17 mediates the upregulation of NCOA3 and CLU noted after ERβ expression
Although the targets of the miR-17-92 cluster in colon are not well characterized, we used anticorrelation between the ERβ-mediated transcriptome in SW480 cells and bioinformatically predicted targets of miR-17 to infer potential effects. Two predicted targets were Expression of miR-9 is activated by MYC, which directly binds to the miR-9-3 locus (73,88) miR-106a miR-106a was upregulated in the high c-MYC state in a human B-cell line (69) implicated in colorectal cancer, the nuclear receptor coactivator NCOA3 (SRC-3) and CLU. NCOA3 may be a direct target of miR-17, based on their complementing nucleotide sequences with one conserved 8mer site at position 714-720 of NCOA3 3ʹ-untranslated region and one conserved 7mer-m8 site at position 1296-1302. In human colon cancer HCT116 cells, miR-17 has been reported to repress CLU levels, which contributed to stimulated angiogenesis and cell growth (81) . Both NCOA3 and CLU were upregulated in ERβ-expressing cells compared with controls (29) . We confirmed that NCOA3 was upregulated both at the mRNA and protein level ( Figure 3E ). This led to the hypothesis that ERβ through MYC and miR-17 regulates a cascade of CLU and NCOA3 activity ( Figure 3F ). As NCOA3 regulates the transcriptional activity of ERβ (82, 83) , this may also constitute a feed-forward loop. To investigate whether the regulations were a direct consequence of the ERβ-mediated downregulation of the miR-17-92 cluster, SW480 cells were transfected with a miR-17 inhibitor to emulate the downregulation of miR-17. Indeed, inhibition of miR-17 led to the upregulation of CLU and NCOA3 ( Figure 3G ) and conversely, when we overexpressed miR-17 in SW480-ERβ cells, using a miR-17 mimic, CLU and NCOA3 levels were correspondingly decreased ( Figure 3H ). This confirms that their upregulation in ERβ-expressing SW480 cells is a consequence of the repressed miR-17 levels. Thus, we have dissected a pathway where ERβ regulates its own coactivator through MYC and miR-17.
ERβ modulates miR-200a/b and epithelial-mesenchymal transition markers
We noted that when ERβ is expressed, the morphology of the cells is significantly changed ( Figure 4A ). The cells adopt a more stretched out and adhesive phenotype that also exhibits reduced migration ( Figure 4B ). This coincides with a strong downregulation of miR-200a and miR-200b in ERβ-expressing cells ( Figure 2B ). Studies in breast cancer cells have established that the miR-200-family repress epithelial-mesenchymal transition through the downregulation of repressors of E-cadherin expression, ZEB1 and ZEB2 (84) . The downregulation of miR-200a/b in SW480 cells coincided with an upregulation of ZEB1 and a downregulation of E-cadherin ( Figure 4C ), whereas ZEB2 was not expressed at detectable levels. As this pathway has not been studied in colon cancer cells, we investigated whether the changed levels of ZEB1 and E-cadherin were a result of the ERβ-mediated repression of miR200a/b. To test this, we re-introduced miR-200a/b into SW480-ERβ cells using mimics. We show that both miRNAs repressed ZEB1 while increasing E-cadherin mRNA and protein levels ( Figure 4D) Figure 4E ).
Cell-specific effects
To explore whether ERβ might have this effect also in advanced colon cancer, we selected the cell line SW620 for further experiments. This cell line originates from the same patient as SW480, but was isolated from a metastatic lymph node 1 year later. Transient transfection of ERβ resulted in higher levels of its mRNA as compared with the stably transfected SW480 cells; functional ERβ receptors, however, showed similar number of expression ( Figure 1B) . We investigated the regulations of MYC and a number of miRNAs 48 h after ERβ transfection using real-time PCR, however, we did not identify the same changes in SW620. It is possible that ERβ does not mediate the same protective mechanism in more advanced and invasive stages, or that stable expression is required. In conclusion, we show that the previously established effect of ERβ on colon cancer proliferation, involves regulation of the miR-17-92 cluster, and that morphology and migration, and regulation of miR-200a/b-ZEB1-E-cadherin levels, are affected by ERβ in SW480 cells.
Discussion
The aim of this study was to investigate whether ERβ expression impacts miRNA regulation in colon cells and to begin dissecting its potential influence. Here, we present evidence that introduction of ERβ in SW480 colon cancer cells induces significant changes in the miRNA pool. To our knowledge, this is the first study to show that expression of ERβ plays an important role in regulating miRNAs in colon cells. We have identified and confirmed 27 miRNAs to be changed following ERβ expression ( Figure 2 ) and most of these miRNAs are implicated as deregulated in different cancers (85) (86) (87) . We further show that many of the regulated miRNAs have predicted or confirmed mRNA targets that were concordantly changed upon ERβ expression (Supplementary Figure 2 , available at Carcinogenesis Online). Using functional studies, we show that the miRNA regulations play a critical role affecting proliferation, apoptosis and migration ( Figures 3 and 4) . We conclude that parts of the ERβ-induced transcriptome changes and functions are due to changes in miRNA expression, highlighting the complexity of gene regulation.
Twenty-three of the changed miRNAs have an ERβ chromatinbinding site in proximity (<100 kb) to the chromosomal location of the stem-loop of the miRNA (Table II) . This observation suggests that several miRNAs are directly regulated by ERβ, offering insight into ERβ function in addition to mRNA transcription. ERβ chromatinbinding sites have only been established for breast cancer cells, and further binding studies in colon cancer cells are needed to prove a direct mechanistic role.
ERβ also regulates several other transcription factors in these cells (29) , which may control their own set of miRNAs. We show that several miRNA regulations, including the repression of the oncogenic miR-17-92 cluster, are a consequence of the ERβ-driven downregulation of MYC ( Figure 3B and Supplementary Figure 3B , available at Carcinogenesis Online). The miR-17-92 cluster was also reported as regulated by ERβ in breast cancer MCF-7 cells (53), whereas overlap of other miRNAs was low between these two studies. Some miRNAs have both an ERβ and a MYC-binding site in their proximity (e.g. miR-9-3, mirR-106a, miR-135a-1) and it is possible that ERβ finetunes their regulation both directly and via MYC.
The proposed target gene of miR-17, NCOA3 and its downstream targets were changed in ERβ-expressing cells ( Figure 3E ), suggesting that ERβ influences these genes through its regulation of MYC/ miR-17. We confirmed that NCOA3 was upregulated as a consequence of miR-17 silencing and repressed as a consequence of miR-17 induction ( Figure 3G and H) , as well as downstream target MYB (Supplementary Figure 3D , available at Carcinogenesis Online). As NCOA3 also activates ERβ and functions as a histone acetyltransferase, making target genes available for transcription, this pathway is important for ERβ's transcriptional action. Further studies are needed to dissect its exact contribution. The upregulation of NCOA3 is likely to be beneficial in a clinical perspective because overexpression of NCOA3 is associated with prolonged overall survival and decreased probability of death in colon cancer (88) . We further demonstrate that the ERβ-mediated decrease in cell proliferation can be reversed by re-introduction of miR-17 ( Figure 3C ). Silencing of miR-17 also increased cell death during DNA-damaging conditions ( Figure 3D ). Although we have previously suggested that ERβ increases DNA repair in colon cells, we propose that the axis miR-17/CLU is responsible for increased apoptotic capacity and that other ERβ-mediated mechanisms, including those described in refs 29 and 89, are responsible for increased DNA repair. These separate pathways are of potential importance for future treatments of colon cancer patients who have developed resistance to chemotherapy. As the entire miR-17-92 cluster was downregulated in the ERβ-expressing cells, the combined effect of all members may play an even more significant role. We explored whether ERβ would mediate the same mechanism in more advanced cancers. Transient expression of ERβ in the metastatic SW620 cells did not repress MYC nor downstream miRNAs (data not shown). As we and others have found that ERβ frequently represses MYC in less metastatic cell lines, ERβ may not mediate the same protective mechanism in more advanced and invasive stages, which have major abnormalities. This area requires further investigation in the future. This indicates that miR-17 inhibitors in combination with chemotherapy may render colon tumors more sensitive to treatment, whereas ERβ activation, increasing DNA repair and attenuating proliferation, may be most beneficial from a prevention or early-stage treatment perspective.
MiR-200a/b was strongly downregulated as a consequence of ERβ expression ( Figure 2B ) along with increased ZEB1 and decreased E-cadherin ( Figure 4C ). After introduction of the miR200a/b mimics, the levels of ZEB1 and E-cadherin returned to the levels resembling those of control cells where ERβ is not expressed ( Figure 4D ). Although restoration of miR-200a has been shown to repress migration in mammary epithelial cells (90) , its downregulation was accompanied by lower migration in SW480 cells. Scratch assay after transient miR-200b mimic transfection indicated no significant change in migration (data not shown). Further studies are needed to explore the functional consequences of this regulation in colon cancer cells. Of note is that the effects of miR-200a/b are multiple and cell specific. We observed that miR200a/b mimics also increased MYC expression (Supplementary Figure 3C , available at Carcinogenesis Online) and that related miR-200c has been reported to increase proliferation in colorectal cancer (91) . Thus, the ERβ-mediated direct downregulation of MYC is enhanced by the concurrent downregulation of miR-200a/b. We see a similar pattern indicated in the regulation of another oncogene, MYB: a potential regulation both through a direct mechanism by ERβ binding to the MYB locus (29) as well as through the miR-17 cascade ( Figure 3F and Supplementary Figure 3D , available at Carcinogenesis Online). These constitute examples of how ERβ represses oncogenes (MYC and MYB) through multiple pathways.
We did not observe any ligand-dependent regulations by ERβ. This correlates to previous observations that ERβ when expressed exogenously in colorectal cancer cell lines often exhibit ligand-independent behavior. This does not imply that ERβ does not rely on conformational changes or is ligand independent when endogenously expressed in vivo. In cell lines, high levels of growth factors and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways along with endogenous estrogen synthesis (92) may activate ERβ. Thereby, high enough levels of the active conformation may be present to fully activate the limited endogenous templates. By performing radiolabeled ligand-binding assays, we ascertained that the levels of exogenously expressed ERβ are within 'physiological' ranges and that it binds ligand ( Figure 1B) . We cannot, however, exclude that non-genomic effects contribute.
In conclusion, we show novel data demonstrating that introduction of ERβ in colon cancer cells induces changes in the miRNA pool, resulting in subsequent mRNA regulations and functional effects. We illustrate corresponding regulation cascades and functional impacts. We propose that the capacity of miRNAs to target multiple pathways help elucidate the genome-wide antitumorigenic regulations mediated by ERβ in colon cancer cells. As ERβ appears to have a significant potential in preventing or attenuating colon cancer development, our results provide insights into the mechanism whereby ERβ acts in the colon and can aid in the development of better diagnostic tools, prevention and treatment of colon cancer. Supplementary Figures 1-3 and Tables 1-2 
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